Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIb Dose-finding Study to Evaluate Safety and Efficacy of Different Subcutaneous Doses of BI 655130 in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP)
收藏DataCite Commons2025-03-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009753/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130
compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at
Week 16. The target dose(s) will be estimated from the model by incorporating information on
the minimum clinically relevant effect and accounting for safety.
Supportive dose-ranging assessments will also be done on pre-specified secondary endpoints.
提供机构：
Vivli
创建时间：
2024-01-12
